Mirena Lawsuit Litigation Moves Forward
2 Pages
English

Mirena Lawsuit Litigation Moves Forward

-

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Mirena Lawsuit Litigation Moves Forward Amidst updates in the litigation ofMirena lawsuita new study published in Obstetrics & Gynecology has revealed that medication may not be able to alleviate the bleeding and spotting experienced by some patients in the first three

Subjects

Informations

Published by
Published 27 September 2014
Reads 1
Language English
Mirena Lawsuit Litigation Moves Forward
Amidst updates in the litigation ofMirena lawsuita new study published in Obstetrics & Gynecology has revealed that medication may not be able to alleviate the bleeding and spotting experienced by some patients in the first three months of implantation.
https://www.facebook.com/mirenalawsuitsettlements
The research, published online April 5th, 2013 indicated that neither tranexamic acid (500 mg/day) nor mefenamic acid (500 mg/day) alleviated bleeding and spotting in women who suffered the side effects within 90 days of using the contraceptive. The drugs only reduced the number of bleeding days by six and three.
The study, which screened 204 women, was designed to identify a 25% reduction in bleeding and spotting days. 85 percent of the patients contained in the research reported an overall satisfaction with the Mirena IUD. However, it is noteworthy to add that Bayer Healthcare Pharmaceuticals, the company who manufactures Mirena supported this research, according to Medscape.com.
This may be part of the reason why the mounting litigation ofMirena Lawsuit Settlement, brought on behalf of women who say the device can spontaneously migrate within a woman's body and cause a range of side effects, was not described the article.
Women who have filed Mirena lawsuits name the presence of abscesses, uterine perforations, infection, ectopic pregnancies, and other injuries stemming from the plastic, t-shaped intrauterine device. These side effects have also been cited in adverse event reports filed with the U.S. Food and Drug Administration (FDA). Plaintiffs in Mirena-related claims also say Bayer failed to adequately warn about the risk of device migration to result from use of the IUD. (In re: Mirena IUD Products Liability L itigation, MDL No. 2434 (JPML)
The Mirena IUD was approved by the FDA in 2000 as an intrauterine birth control device. In 2009, the levonorgestrel-releasing IUD's list of uses expanded to include the treatment of heavy menstrual bleeding in women who used Mirena as a form of birth control.
Since then, the litigation of lawsuits from patients who used this product has grown. On April 8th, 2013, just a few days after the Mirena side effects study was published in Obsetrics & Gynecology, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a Transfer Order to move all federally -filed claims to the U.S. District Court for the Southern District of New York. According to the Order announced April 8th, approximately 40 Mirena lawsuits had been filed in 17 federal jurisdictions in the U.S.
Mirena IUD lawsuits seek compensation for medical expenses, lost wages, pain and suffering and other damages incurred by the patient's injury.
)